Skip to main content

Catalyst Calendar

Scope
Catalyst

Tue, Sep 15, 2026

1 updates
LLY
6:45 AM

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings from ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes, reaffirmed its safety

Presentation / Abstract • Phase 3EASD symposium presentation Wed, Sep 30, 2026, 8:30 AM CESTlilly.com

Mon, Aug 31, 2026

1 updates
LLY
7:00 AM

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials Systemic inflammation and metabolic outcomes

Trial Results • Phase 352-week results Mon, Aug 31, 2026lilly.com

Thu, Jul 23, 2026

1 updates
LLY
6:45 AM

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost

Trial Results • Phase 3Topline results Thu, Jul 23, 2026lilly.com

Thu, Jul 9, 2026

1 updates
LLY
7:30 AM

/C O R R E C T I O N -- Eli Lilly and Company/

In the news release, Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment, issued July 9, 2026 by Eli Lilly and Company over PR Newswire, we are advised by the company that changes have been

Presentation / AbstractAAIC oral presentation Mon, Jul 13, 2026, 9:00 AMlilly.com